ChAdOx1 LS2

ChAdOx1 LS2 is a novel malaria vaccine candidate developed by the University of Oxford, specifically by Adrian Hill’s group. It utilizes the ChAdOx1 platform, which is a replication-deficient chimpanzee adenoviral vector engineered to express malaria antigens. In this case, the vector encodes a dual antigen insert (LS2) comprising Liver Stage Antigen 1 (LSA1) and Liver Stage Associated Protein 2 (LSAP2), both of which are associated with liver-stage Plasmodium falciparum infection. The vaccine works by delivering genetic material encoding these antigens into host cells after intramuscular injection, prompting an immune response—primarily CD8+ T-cell mediated—against malaria without causing disease. The first-in-human clinical trial assessed safety, immunogenicity, and efficacy in healthy UK adults; while it was well tolerated and induced strong immune responses, it did not confer protection against controlled human malaria infection in this study[3][5][6].

Other names

VAC067VAC-067VAC 067